Initially, Concert will get an unspecified upfront payment while the two work on one unnamed drug, but the partnership could expand significantly from there. Should Celgene buy in to Concert’s technology and “exercise its program options,” Concert could get up to $300 million in development, regulatory and sales milestones for each drug the Summit, NJ-based biotech utilizes Concert’s technology to help develop and advance, as well as royalties should Celgene ultimately ever sell those drugs. Concert provided little additional information about the drugs the two will develop, only indicating that the two companies will target the areas of cancer and inflammation, and Tung declined to specify further on Monday. RBC Capital analyst Michael Yee speculated in a research note Monday that one of the drugs is Concert’s CTP-221, a deuterium-modified version of Celgene’s blockbuster myeloma drug lenalidomide (Revlimid). Concert said in December that it expects to finish pre-clinical testing of CTP-221 and seek FDA clearance to begin clinical trials in 2013.
Celgene is developing novel orally available small molecules that inhibit the production of multiple proinflammatory mediators including interleukin-2 (IL-2), IL-12, interferon-gamma, TNF-alpha, leukotrienes, and nitric oxide synthase.
Celgene is developing novel orally available small molecules that inhibit the production of multiple proinflammatory mediators.
Our lead investigational drug, CC-10004 (apremilast) is an oral compound that is being studied in multiple Phase III clinical trials for the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases. We successfully completed our early stage studies, demonstrating clinical activity and tolerability and meeting safety endpoints in a placebo controlled proof-of mechanism trial in moderate-to-severe psoriasis and psoriatic arthritis. With the initiation of six multi-center international clinical trials, we are advancing the clinical development of CC-10004.
CC-11050 is currently in Phase I clinical trials for chronic inflammatory diseases.
CC-10004 and CC-11050 are investigational products and are not approved for any indications.
CC-10004 (apremilast) is Otezla. CTP-730 could be added to Otezla to make it a much more effective drug. If considerably more effective, it could make Otezla the number one arthritis drug on the market. Which arthritis is a huge market. Otezla isn't as effective as injectable arthritis drugs, but what if it could be? If CTP-730 could make it as effective, slightly less effective, or more effective, then you've got yourself a winner.
if Concert and Celgene got together and made a deuterated, more effective, Revlimid it would be huge for both companies (I own both). For celgene it would allow them to dominate the market in MM as new patents would extend beyond the current Revlimid patents.
For Concert, well, even 5% of a 5+ billion dollar drug would be substantial for a company this small.
I know. But what's strange is they chose CTP-730 instead of CTP-221. Does that mean CTP-730 isbetter than CTP-221? The results for CTP-221 were already amazing. Just look it up. I've tried to post the results on here, but Yahoo hasn't let me.